Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

The retinal nerve fiber layer (RNFL) has no myelin and can thereby be considered to be a highly enriched axonal tissue •Changes in the RNFL and macula probably reflect mechanisms of inflammation ...

Deep learning has emerged as a powerful tool in the field of medical imaging, particularly in the diagnosis of retinal diseases using Optical Coherence ... such as macular edema and age-related ...

OT asked the experts what delegates can expect to hear in clinical imaging, from skills development to applications of the latest techniques, at 100% Optical 2025 ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Macular degeneration, also known as age-related ... To help confirm a diagnosis, eye doctors rely on optical coherence tomography (OCT). This non-invasive form of imaging relies on distortions ...

FAZ area deteriorated in stable eyes with proliferative diabetic retinopathy and macular capillary nonperfusion ... “With the advent of optical coherence tomography angiography (OCTA), it ...

Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69 , 2085–2092 (2007). Article CAS Google Scholar ...

The global ophthalmic diagnostic equipment market is poised for steady growth, with projections indicating an increase from ...

The 3D OCT (Optical Coherence Tomography) machine in the Eye Clinic helps diagnose macular degeneration as well as other eye conditions affecting those with diabetes, which can lead to sight loss ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...